Audentes Therapeutics (BOLD) Misses Q1 EPS by 24c
Tweet
Share
E-mail
Get Alerts BOLD Hot Sheet
Join SI Premium – FREE
Audentes Therapeutics (NASDAQ: BOLD) reported Q1 EPS of ($1.13), $0.24 worse than the analyst estimate of ($0.89).
For earnings history and earnings-related data on Audentes Therapeutics (BOLD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wex, Inc. (WEX) Tops Q2 EPS by 29c; raises guidance
- Oceaneering (OII) Tops Q2 EPS by 19c
- First Bancorp (FNLC) Tops Q2 EPS by 85c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
